tiprankstipranks
Advertisement
Advertisement
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
28d ago
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
Premium
The Fly
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
28d ago
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
29d ago
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
1M ago
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
1M ago
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication
1M ago
Soligenix receives positive opinion from EMA for OOD request for dusquetide
PremiumThe FlySoligenix receives positive opinion from EMA for OOD request for dusquetide
2M ago
Soligenix Provides Shareholder Update on Rare Disease Pipeline
Premium
Company Announcements
Soligenix Provides Shareholder Update on Rare Disease Pipeline
3M ago
Soligenix Establishes At-The-Market Equity Offering Program
Premium
Company Announcements
Soligenix Establishes At-The-Market Equity Offering Program
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100